TELA Bio, Inc.

TELA Bio is a commercial-stage medical device company specializing in soft-tissue reconstruction solutions for surgical repair procedures. The company's primary product portfolio consists of OviTex Reinforced Tissue Matrix products, which are derived from ovine rumen combined with polypropylene fibers. These products are designed for hernia repair and abdominal wall reconstruction, with specialized variants developed for plastic and reconstructive surgery applications and for use in laparoscopic and robotic-assisted surgical procedures.

The company generates revenue through direct sales of its OviTex product line, marketed through an in-house sales force primarily serving the United States market. The OviTex portfolio addresses clinical needs across general surgery and plastic and reconstructive surgery specialties, with products tailored to different surgical approaches including open, laparoscopic, and robot-assisted techniques.

TELA Bio operates with approximately 209 full-time employees and is headquartered in Malvern, Pennsylvania. The company was incorporated in Delaware in 2012 and trades on the Nasdaq exchange. Its commercial operations remain concentrated in the United States, where it distributes its reinforced tissue matrix products directly to healthcare facilities and surgeons.